Calgary Myopia Control: What’s the Latest on Combining MiSight Lenses with Atropine Drops in 2026?

As a professional in the optical lab world for many years, I’ve seen firsthand the increasing focus on myopia control – and rightfully so. Childhood myopia is on the rise, and the implications for long-term eye health are significant. Here in Calgary, AB, and across the country, parents are understandably eager to explore every effective option. One of the most promising areas of development involves combining MiSight 1 Day contact lenses with low-dose atropine eye drops. This article will break down what the current research suggests about this combination in 2026, covering treatment protocols, what to expect, and crucial monitoring aspects.

Why Combine MiSight and Atropine? Understanding the Synergistic Effect

For years, low-dose atropine (typically 0.01% to 0.05%) has been a cornerstone of myopia management. It works by affecting the focusing mechanisms of the eye, slowing down the rate at which the eyeball elongates—the primary driver of nearsightedness. However, atropine alone doesn’t always halt progression completely, and higher concentrations can cause side effects like light sensitivity and difficulty with near vision.

MiSight 1 Day lenses, on the other hand, utilize a unique dual-focus design. They have concentric zones – a central zone for clear distance vision, and surrounding zones with defocus power. This technology creates a myopic defocus on the peripheral retina, which is thought to signal the eye to slow its growth. The key is that these two approaches work on different pathways. Atropine affects the eye’s focusing system, while MiSight alters the optical signal to the retina. Combining them appears to create a synergistic effect, potentially leading to greater myopia control than either treatment alone.

Recent studies support this. Research indicates that pairing 0.01% atropine with MiSight 1 Day lenses can demonstrably reduce myopia progression and axial elongation – that is, the lengthening of the eyeball. A retrospective study demonstrated benefits over using 0.01% atropine as a standalone therapy. Similarly, investigations have shown significant reductions in both progression and axial length when combining MiSight lenses with 0.05% atropine in children experiencing rapidly progressing myopia.

What Does a Typical Treatment Protocol Look Like?

There's no single, universally accepted protocol, as individual treatment plans should be determined by an optometrist specializing in myopia control. However, here's a general overview of what you can expect:

1. Comprehensive Eye Exam: A thorough assessment is crucial, including cycloplegic refraction (using eye drops to temporarily relax the focusing muscles) to accurately measure the degree of myopia and assess overall eye health.
2. Atropine Prescription: Most practitioners are starting with 0.01% or 0.05% atropine. While higher concentrations were previously used, the lower doses minimize side effects like blurry near vision and light sensitivity.
3. MiSight Lens Fitting: Proper contact lens fitting is essential. MiSight lenses aren't a one-size-fits-all solution, and a skilled optometrist will carefully evaluate corneal curvature, tear film, and other factors to ensure a comfortable and effective fit.
4. Initial Lens Wear: Typically, children will start by wearing the MiSight lenses during the day, gradually increasing wear time as tolerated.
5. Atropine Drop Administration: Atropine drops are usually administered nightly.

It's important to remember that this isn’t a “set it and forget it” approach. Success depends on consistent adherence to the prescribed regimen and regular monitoring.

How Often Should My Child Be Monitored?

Regular follow-up appointments are absolutely vital. These aren’t just about checking vision; they’re about assessing the effectiveness of the treatment and making adjustments as needed. Here's a typical monitoring schedule:

• Initial Check-Up (1-2 weeks): To evaluate lens fit, comfort, and initial response to both treatments.
• 3-Month Check-Up: Assess myopia progression, measure axial length, and evaluate any side effects.
• 6-Month Check-Ups: Continued monitoring of progression, axial length, and overall eye health.
• Annual Check-Ups: Comprehensive evaluation to refine the treatment plan.

What most people don’t realize is that axial length measurement is a key indicator of myopia control success. Simply tracking changes in eyeglass prescription isn’t enough. Axial length provides a direct measure of how much the eyeball is elongating. Your eye care practitioner should be using modern diagnostic tools, such as optical biometry, to accurately track this parameter.

What About Costs and Alberta Health Coverage?

Myopia control treatments, including MiSight lenses and atropine drops, are typically considered an out-of-pocket expense for Albertans aged 19-64. Alberta Health Care ONLY covers eye exams for children under 19 and adults 65+. The cost of MiSight lenses will vary depending on the prescription and the optometrist, but expect to pay significantly more than for standard contact lenses. Atropine drops are relatively inexpensive. It's vital to discuss the financial implications with your eye care practitioner upfront.

Are There Any Downsides or Considerations?

While the combination of MiSight and atropine appears promising, it’s not without considerations:

• Compliance: Both contact lens wear and nightly atropine drops require consistent adherence.
• Side Effects: While low-dose atropine minimizes side effects, some children may still experience mild blurriness or light sensitivity.
• Not a Cure: Myopia control aims to slow progression, not eliminate nearsightedness entirely.
• Individual Variability: Not every child will respond equally to treatment.

What’s New in 2026?

The field of myopia control is constantly evolving. In 2026, we're seeing a greater emphasis on personalized treatment plans, tailoring the atropine concentration and lens design to each patient’s unique needs. Furthermore, longer-term studies, like the 5-year data from APMMS 2026, are providing valuable insights into the long-term efficacy and safety of these combination therapies.

It's an exciting time for myopia management, and the combination of MiSight 1 Day lenses and low-dose atropine represents a significant advancement in our ability to protect children’s vision.

If you are interested in learning more about myopia control options, Contact Us today.